摘要
目的探讨吉非替尼联合吉西他滨和顺铂(GP)化疗方案对晚期表皮生长因子受体(EGFR)突变非小细胞肺癌(NSCLC)患者疗效及血清肿瘤标志物的影响.方法选择2019年1月—2020年9月我院收治的84例晚期EGFR突变NSCLC患者,将使用GP化疗方案的42例患者纳入对照组,将使用吉非替尼联合GP化疗方案的42例患者纳入观察组.对比两组的临床疗效、血清肿瘤标志物水平、无进展生存期及不良反应发生情况.结果观察组的客观缓解率、疾病控制率分别为35.71%、69.05%,均高于对照组,组间差异有统计学意义(P<0.05).治疗后,观察组的神经元特异性烯醇化酶、细胞角蛋白19片段表达水平均低于对照组,组间差异有统计学意义(P<0.05).观察组的无进展生存期为(10.95±1.34)个月,高于对照组的(7.97±1.22)个月,差异有统计学意义(P<0.05).观察组的白细胞缺乏、血小板缺乏发生率分别为28.57%、9.52%,均低于对照组,组间差异有统计学意义(P<0.05).结论采用吉非替尼联合GP化疗方案治疗晚期EGFR突变NSCLC患者的效果理想,能抑制血清神经元特异性烯醇化酶、细胞角蛋白19片的表达,降低化疗所致的血液毒性反应,临床应用价值高.
Objective To investigate the effects of gefitinib combined with gemcitabine and cisplatin(GP)chemotherapy on the efficacy and serum tumor markers in patients with advanced epidermal growth factor receptor(EGFR)mutation nonsmall cell lung cancer(NSCLC).Methods 84 patients with advanced EGFR-mutated NSCLC admitted to our hospital from January 2019 to September 2020 were selected.42 patients using GP chemotherapy regimen were included in the control group,and 42 patients using gefitinib combined with GP chemotherapy regimen were included in the observation group.The clinical efficacy,serum tumor markers,progression-free survival and adverse reactions were compared between the two groups.Results The objective remission rate and disease control rate in the observation group were 35.71%and 69.05%,respectively,higher than those in the control group,and the differences between the groups were statistically significant(P<0.05).After treatment,the expression levels of neuron specific enolase and cytokeratin 19 fragment in the observation group were lower than those in the control group,and the differences between the groups were statistically significant(P<0.05).The progression-free survival in the observation group was(10.95±1.34)months,higher than(7.97±1.22)months in the control group,and the difference was statistically significant(P<0.05).The incidences of leukocyte deficiency and platelet deficiency in the observation group was 28.57%and 9.52%,respectively,lower than those in the control group,and the differences between the groups were statistically significant(P<0.05).Conclusion Gefitinib combined with GP chemotherapy has an ideal effect on patients with advanced EGFR-mutant NSCLC.It can inhibit the expression of 19 tablets of neuron-specific enolase and cytokeratin in serum,and reduce the blood toxicity induced by chemotherapy.It has high clinical application value.
作者
逯仁波
LU Renbo(Department of Oncology,Harbin First Hospital,Harbin Heilongjiang,150000,China)
出处
《反射疗法与康复医学》
2022年第9期123-125,共3页
Reflexology And Rehabilitation Medicine
作者简介
逯仁波(1982-),男,黑龙江哈尔滨人,硕士研究生,主治医师,研究方向:肿瘤的分子靶向治疗结合中医药抗肿瘤治疗。
